Abstract
In June of 2008 we initiated a breast clinic designed to serve patients regardless of funding status. We analyzed age, race, tumor size, nodal status, estrogen, progesterone, and her-2-neu status. We compared our results to NSABP B-06 (nodal status), B-15 (estrogen, progesterone, and Her-2-neu receptor status), B-18, and B-27 (age, race, and tumor size) to determine whether our patient population was similar to patients included in these trials. Forty-nine patients with newly diagnosed breast cancer were treated during our first year (53 total cancers). Eight patients had noninvasive cancer; 45 had invasive disease. The mean age was 52.2 ± 12.2 years compared to a mean age of 48.4 ± 9.8 years in the B-06 trial (P = 0.005). Thirty six patients were African American (74%) compared to 10% and 12% in the NSABP B-18 and B-27 trials (P < 0.00001). A total of 23 of our patients with invasive cancer had involved axillary lymph nodes which was statistically more common than the 35.3% of node positive patients in the B-06 trial (P = 0.03). Tumor size (3.6 ± 3.3 cm), estrogen (54.4%), and progesterone (52.8%) receptor status were similar to NSABP trials. Only 6 (13.3%) of our patients were considered Her-2-neu positive compared to 29.4 % in the B-15 trial which was significantly less prevalent (P = 0.02). Significantly different demographic and tumor characteristics were identified in our inner city breast cancer patient population compared to NSABP patients. These results question the validity of using recommendations from large cooperative group trials in the development of treatment plans for our inner city patient population.
Get full access to this article
View all access options for this article.